drugset

drugset / Trial / NCT02629393

Study of ORGN001 (Formerly ALXN1101) in Neonates, Infants and Children With Molybdenum Cofactor Deficiency (MOCD) Type A

NCT02629393 ↗

Phase 2/3 Completed 5 enrolled Origin Biosciences

NaSingle-groupOpen-labelTreatment

Summary

To evaluate the safety and efficacy of ORGN001(formerly ALXN1101) in neonate patients with MoCD Type A

Timeline

Start: 2016-05
Primary completion: 2022-09
Completion: 2022-10

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	ORGN001	Unknown	—	—

Indications